NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025

Concepts

• runcorn
• pharmaceutical products
• nhs framework agreement
• branded medicines - tranche b
• ravulizumab
• eculizumab
• branded medicines - eculizumab
• nhs framework agreement for branded medicines - tranche b - nofe & mae
• mae
• branded medicines - tranche b - nofe

Location

Description

NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 Offer reference number: CM/PHR/24/5680 CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026

CPV Codes

• 33600000 - Pharmaceutical products

Indicators

• Contract is suitable for SMEs.

Other Information

To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk Document No. 05c - Volume Discounts or Additional Products Offer Schedule - CM-PHR-24-5680 Document No. 05c - Volume Discounts or Additional Products Offer Schedule - CM-PHR-24-5680.xls Document No. 09 - Tender Design and Instructions on Completing the Offer Schedule Document No. 09 - Tender Design and Instructions on Completing the Offer Schedule.doc Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements Document No. 04b - Assessment Criteria, Stability Protocol and Additional Specification Requirements.docx Document No. 07a - Quality Control Technical Sheet Document No. 07a - Quality Control Technical Sheet.doc Document No. 07b - Quality Assurance Policy to Support the National Contract Procurement of Licensed Medicines v6 (Issued October 2023) Document No. 07b - Quality Assurance Policy to Support the National Contract Procurement of Licensed Medicines v6 (Issued October 2023).docx Document No. 08 - Confidential Information Schedule - CM_PHR_24_5680 Document No. 08 - Confidential Information Schedule - CM_PHR_24_5680.xls Document No. 05 - Selectt Offer Schedule Instructions - CM-PHR-24-5680 Document No. 05 - Selectt Offer Schedule Instructions - CM-PHR-24-5680.docx Document No. 06 - Form of Offer - CM_PHR_24_5680 Document No. 06 - Form of Offer - CM_PHR_24_5680.doc Document No. 05a(ii) - Selectt Offer Schedule - CM_PHR_24_5680_02 Document No. 05a(ii) - Selectt Offer Schedule - CM_PHR_24_5680_02.xml Document No. 10 - Participating Authorities - CM_PHR_24_5680 Document No. 10 - Participating Authorities - CM_PHR_24_5680.xls Document No. 02 - Terms of offer Document No. 02 - Terms of offer.docx Document No. 04a - Quality Assurance Process Document No. 04a - Quality Assurance Process.doc Document No. 05a(i) - Selectt Offer Schedule - CM_PHR_24_5680_01 Document No. 05a(i) - Selectt Offer Schedule - CM_PHR_24_5680_01.xml Document No. 05b(i) - Tender Product Listing and Usage - CM_PHR_24_5680_01 Document No. 05b(i) - Tender Product Listing and Usage - CM_PHR_24_5680_01.xlsx Document No. 03 - Framework Agreement and Terms and Conditions - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab - 1 September 2025 Document No. 03 - Framework Agreement and Terms and Conditions - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab - 1 September 2025.docx Document No. 01 - Invitation to offer covering letter Document No. 01 - Invitation to offer covering letter.docx Document No. 05b(ii)- Tender Product Listing and Usage - CM_PHR_24_5680_02 Document No. 05b(ii)- Tender Product Listing and Usage - CM_PHR_24_5680_02.xlsx